UCB Estimates Lifted as BofA Expects Continued Pricing Tailwind in FY26

09:12 AM EST, 12/08/2025 (MT Newswires) -- BofA Global Research raised its EPS forecasts for UCB (UCB.BR) following its upgraded 2025 guidance, expecting positive momentum from pricing to continue as the Belgian biopharmaceutical company heads into the next year. "Guide raise supports strong momentum and leverage in our view, alongside a good period of positive scrip trends offering a good setup into 26E," the research firm said Monday. "We now think a higher portion of the guide upgrade and pricing tailwind seen could continue into FY26 than our original assessment. We estimate the temporary pricing benefit of uncontracted [hidradenitis suppurativa] volumes could have contributed a maximum cEur100m sales to 2H (Eur150m in extreme scenarios). Other drivers of the cEur0.3bn guide upgrade vs cons are less clear, though we expect these to be more durable especially if better pricing was from higher net prices and lower bridge volumes." Analysts expect UCB to post 7.7 billion euros in sales for full-year 2025, raising their sales estimates for the company's psoriasis and anti-inflammatory drug Bimzelx to 2.3 billion euros from 2 billion euros. For 2026, projected sales were increased by 300 million euros on the back of higher pricing assumptions. The EPS forecasts for the company were also increased to 9.04 euros from 7.87 euros for 2025 and to 11.03 euros from 10.35 euros for 2026, while the projection for 2027 was nudged up to 13.78 euros from 13.52 euros. The buy rating on the stock was reaffirmed, with a price objective of 280 euros.